-
LIQUIK Study Interim Results to Showcase Lucence’s Liquid Biopsy Advancements at WCLC 2023
•
Precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto, California, has announced that the interim results of the LIQUIK study, a prospective international multicenter liquid biopsy study for lung cancer, will be reported at the IASLC 2023 World Conference on Lung Cancer (WCLC) held on…
-
Luye Pharma’s Botawei Receives NMPA Approval for Breast Cancer Treatment
•
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its injectable goserelin acetate in microsphere form, trade-named Botawei, for the treatment of breast cancer in premenopausal and perimenopausal women eligible for hormone therapy. Botawei: A Pioneering Treatment for…
-
ClouDr Partners with Hong Kong Magicure Medical Center to Enhance Cross-Border Medical Access
•
Hangzhou Kang Ming Information Technology Co., Ltd, known as “ClouDr” (HKG: 9955), has entered into a partnership with Hong Kong Magicure Medical Center with the goal of streamlining the supply chain and accelerating domestic access to the world’s leading medical resources in China. This collaboration aims to provide patients with…
-
Mindray Launches TE Air Wireless Handheld Ultrasound Solution in the US Market
•
China-based global device giant Mindray (SHE: 300760) has announced the market launch of its TE Air Wireless Handheld Ultrasound imaging solution in the United States. This innovative device offers healthcare providers (HCPs) a pocket-held scanning tool designed for use across a broad spectrum of clinical scenarios, enhancing diagnostic capabilities at…
-
MSD Plans to Introduce Over 50 New Drugs and Vaccines to China in the Next Five Years
•
Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK), through its China R&D president Li Zhengqing, has shared the company’s pipeline plans with local press. As reported by the China Daily, MSD is planning to introduce over 50 innovative drugs, vaccines, new indications, and companion diagnostics to the Chinese market over…
-
Novo Nordisk and Broad Institute Collaborate on Diabetes and Cardiometabolic Research
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a collaboration with the US academic institution, the Broad Institute, on three cutting-edge research projects focusing on diabetes and cardiometabolic diseases. This strategic partnership aims to drive innovation in the understanding and treatment of these conditions. Type 2 Diabetes Drug Target…
-
Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study
•
Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on a late-stage study for its bispecific antibody (BsAb) Rybrevant (amivantamab). The study investigated the combination of Rybrevant with tyrosine kinase inhibitor (TKI) lazertinib and chemotherapy in treating advanced or metastatic non-small cell lung cancer (NSCLC)…
-
FDA Addresses Looming Migraine Treatment Shortage with Tonix Pharmaceuticals Commitment
•
The US Food and Drug Administration (FDA) is actively engaging with pharmaceutical companies to address an impending shortage of a critical migraine treatment. This follows the UK-based GlaxoSmithKline’s (GSK; NYSE: GSK) decision to discontinue the production of Imitrex (sumatriptan) nasal spray from January 31, 2024. The move has prompted concerns…
